Somatropin Market Size and Share Is Expected to Reach US$ 8.56 Billion and to Register a CAGR of 7.9% By 2027 | Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, GeneScience Pharmaceuticals,

Global Somatropin Market

Overview:

Somatropin is a human growth hormone used for treating the growth hormone deficiency, Prader-Willi syndrome, Turner syndrome and Chronic Renal Insufficiency and many others. Somatropin also stimulates lipid protein, mineral and carbohydrate metabolism, linear growth and tissue growth. Increasing incidences of growth hormone deficiency owing to brain injuries is anticipated to boost growth of the global somatropin market during the forecast period. The International Journal of Molecular Sciences published an article in July 2019, stating that growth hormone deficiency is the most common type of hormone deficiency witnessed in survivors of brain injuries.

The global somatropin market is anticipated to be valued at US$ 5.02 Bn in 2020 and is estimated to exhibit a CAGR of 7.9% during the forecast period.

𝐓𝐨 𝐠𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.coherentmarketinsights.com/insight/request-sample/4062

Impact of Covid-19:

The pandemic has affected clinical trials immensely. According to a survey conducted by Medidata Solutions, Inc on April 23, revealed that 63% survey respondents are not recruiting new people for carrying out the clinical trials, while 43% respondents have decided to postpond their clinical trials. Moreover, ongoing clinical trials must stick to the following safety measures:

• Healthcare professionals must obtain the patients consent via audio or video conference. Medidata Solutions, Inc., conducted a survey on 23 April, 2020, mentioning that 45% of the respondents had opted for virtual consultancy.
• The patient should receive a phone call regarding the screening of COVID-19 symptoms before the patient visits for the trial.
• Assessment of these studies should be carried out in a single outpatient areas.

Drivers:

Rising incidences of growth hormone deficiency is estimated to drive growth of the global somatropin market growth during the forecast period. For instance, the Springer Nature journal published an article in February 2017, stating that growth hormone deficiency in children is found to be ranging from 1.8 to 2.9 in per 10,000 individuals in the United States of America and Europe.

Moreover, the rise in approvals of somatropin products by regulatory authorities like the U.S.FDA is estimated to propel the growth of the global somatropin market growth during the forecast period. For instance, Ferring Pharmaceuticals Inc., gained approval from the U.S. FDA in July 2018, for ZOMACTON, a somatropin injection, for Idiopathic short height, short height due to Turner syndrome and short stature born small for gestational age or growth failure.

𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4062

Restraints:

Key players are focusing on the development of alternative treatments for growth hormone deficiency, which is anticipated to hamper the growth of the global somatropin market during the forecast period. For instance, Pfizer Inc. and OPKO Health Inc. declared the results of phase 3 clinical trials of somatrogen, in October 2019. Somatrogen, is a human growth hormone compound given to children suffering from growth hormone deficiency.

Market Taxonomy:

By Dosage Form:

• Powder
• Solvent

By Application:

• Growth Hormone Deficiency (GHD)
• Turner Syndrome
• Chronic Renal Insufficiency
• Prader Willi Syndrome
• Small for Gestational Age
• SHOX Deficiency
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Key Players:

Key players active in global somatropin market are Ferring Pharmaceuticals, Pfizer Inc., F. Hoffmann-La Roche, Novo Nordisk A/S, Ipsen Inc., Teva Pharmaceutical Industries Ltd., GeneScience Pharmaceuticals, Merck KGaA, Eli Lilly and Company, LG Life Sciences and Sandoz International.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅 @ https://www.coherentmarketinsights.com/promo/buynow/4062

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Dosage Form
     • Market Snippet, By Application
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Key Developments
   • PEST Analysis
4. Global Somatropin Market – Impact of Coronavirus (Covid-19) Pandemic
   • Impact assessment
   • Pre COVID-19 Market Scenario
   • Post COVID-19 Market Scenario
   • Government measures to combat COVID-19
5. Global Somatropin Market, By Dosage Form, 2016 – 2027, (US$ Bn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Powder
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Solvent
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
6. Global Somatropin Market, By Application, 2016 – 2027, (US$ Bn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Growth Hormone Deficiency (GHD)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Turner Syndrome
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Chronic Renal Insufficiency
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Prader Willi Syndrome
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Small for Gestational Age
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • SHOX Deficiency
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
7. Global Somatropin Market, By Distribution Channel, 2016 – 2027, (US$ Bn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)

View Press Release: https://www.coherentmarketinsights.com/press-release/somatropin-market-3320

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837